Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1B | P49286 | 1/20 | 0.45 |
| ▸ | GRIN2C | Q14957 | 3/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | CPS1 | P31327 | 2/20 | 0.40 |
| ▸ | FKBP1A | P62942 | 4/20 | 0.39 |
| ▸ | DRD1 | P21728 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4418261 | 0.79 | MTNR1B (0.41) | MTNR1BGRIN2CFKBP1AKMT2ATP53 | |
| SCHEMBL4414665 | 0.77 | GRIN2C (0.64) | MTNR1BGRIN2CFKBP1AKMT2ATP53 | |
| SCHEMBL4416142 | 0.73 | GRIN2C (0.55) | MTNR1BGRIN2CKMT2ATP53MEN1 | |
| SCHEMBL4424375 | 0.69 | HTT (0.71) | MTNR1BGRIN2CSMN1; SMN2KMT2ARXFP1 | |
| SCHEMBL4416128 | 0.67 | TRPV1 (0.46) | MTNR1BGRIN2CCPS1FKBP1AKMT2A | |
| SCHEMBL13809019 | 0.67 | GRIN2C (0.44) | MTNR1BGRIN2CFKBP1AKMT2ATP53 | |
| SCHEMBL13809245 | 0.66 | RXFP1 (0.45) | MTNR1BGRIN2CKMT2ATP53RXFP1 | |
| SCHEMBL4421922 | 0.66 | KMT2A (0.46) | MTNR1BGRIN2CCPS1FKBP1ASMN1; SMN2 | |
| SCHEMBL4413383 | 0.66 | KMT2A (0.47) | MTNR1BGRIN2CDRD1KMT2ATP53 | |
| SCHEMBL4418814 | 0.65 | MTNR1B (0.48) | MTNR1BGRIN2CPARP1FKBP1ADRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1663983-B1 | N-SUBSTITUTED, 6,8-DIALKOXY-1,2,3,4-TETRAHYDRO-1H-ISOQUINOLINE AS POTASSIUM CHANNELS MODULATORS | 4SC AG (DE) | 2009-01-21 | — | — | EP | disclosed |
| US-20050070570-A1 | Novel potassium channels modulators | 4SC AG (DE) | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070570-A1 | Novel potassium channels modulators | HCN4, KCNA4, KCNN4 | MTNR1B 569/4885GRIN2C 567/4885PARP1 4676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.